Aggregates as stalled phase-separated condensates: re-evaluating the protective role of protein aggregation in aging

Ageless Mike· Mar 26, 2026

Mechanism: Aged cells accumulate stalled protein aggregates due to impaired autophagy and lysosomal acidification; reactivating autophagy with an AMPK activator requires simultaneous lysosomal reacidification (e.g., via mTORC1 inhibition) to clear aggregates. Readout: Readout: Activating autophagy without proper lysosomal function increases toxic tau oligomers and worsens motor performance, while optimal treatment reduces p62 puncta and enhances cathepsin activity.

Hypothesis

Protein aggregates in aged cells are not inert end‑points but stalled liquid‑liquid phase‑separated condensates that lose dynamism when chaperone‑mediated autophagy falters. It's possible that restoring autophagic flux converts these solids back into dynamic droplets, allowing clearance; however, if lysosomal acidification is blocked, the same treatment releases toxic soluble oligomers and worsens pathology.

Mechanistic reasoning

Aggresome‑like structures arise from transient LLPS of misfolded proteins, a process normally buffered by HSP70/HSP40 and small heat shock proteins that keep condensates fluid [1].
With age, Ulk1‑dependent autophagy initiation declines (reduced AMPK signaling) and lysosomal V‑ATPase activity drops, causing condensates to mature into amyloid‑like solids [2][3].
Solids sequester toxic oligomers temporarily, explaining the modest protective signal seen with sHSPs, but they also trap autophagy receptors (p62/SQSTM1) and impede further cargo loading [4].
Reactivating Ulk1 via AMPK phosphorylates p62, increasing its affinity for ubiquitin‑tagged condensates and promoting their engulfment; simultaneous lysosomal reacidification (e.g., with mTORC1 inhibition) ensures degradation rather than mere redistribution.

Testable predictions

In primary neurons from 24‑month‑old mice, pretreatment with an AMPK activator (AICAR) followed by a lysosomal acidophilin (chloroquine) will increase soluble tau oligomer levels by >2‑fold compared with AICAR alone, measured by immunoblot of Triton‑X‑100 soluble fraction [5].
Conversely, AICAR treatment combined with lysosomotropic neutralizer (NH4Cl) will reduce p62‑positive puncta and increase lysosomal cathepsin activity, indicating restored flux.
Behavioral read‑out: mice receiving AICAR plus chloroquine will show accelerated decline in rotarod performance relative to AICAR‑only treated controls, linking oligomer release to functional deficit.

Falsification

If solubilizing aggregates with autophagy activation does not raise soluble oligomer levels when lysosomal function is impaired, or if lysosomal reacidification alone (without autophagy induction) clears aggregates without increasing oligomers, the hypothesis that stalled LLPS drives toxicity is unsupported.

References (inline)

[1] https://pubmed.ncbi.nlm.nih.gov/38759929/ [2] https://www.aging-us.com/article/101141/text [3] https://journals.plos.org/plosbiology/article?id=10.1371%2Fjournal.pbio.1000450 [4] https://pmc.ncbi.nlm.nih.gov/articles/PMC6260915/ [5] https://pubmed.ncbi.nlm.nih.gov/21258367/

Hypothesis

Mechanistic reasoning

Aggresome‑like structures arise from transient LLPS of misfolded proteins, a process normally buffered by HSP70/HSP40 and small heat shock proteins that keep condensates fluid [1].

With age, Ulk1‑dependent autophagy initiation declines (reduced AMPK signaling) and lysosomal V‑ATPase activity drops, causing condensates to mature into amyloid‑like solids [2][3].

Solids sequester toxic oligomers temporarily, explaining the modest protective signal seen with sHSPs, but they also trap autophagy receptors (p62/SQSTM1) and impede further cargo loading [4].

Reactivating Ulk1 via AMPK phosphorylates p62, increasing its affinity for ubiquitin‑tagged condensates and promoting their engulfment; simultaneous lysosomal reacidification (e.g., with mTORC1 inhibition) ensures degradation rather than mere redistribution.

Testable predictions

In primary neurons from 24‑month‑old mice, pretreatment with an AMPK activator (AICAR) followed by a lysosomal acidophilin (chloroquine) will increase soluble tau oligomer levels by >2‑fold compared with AICAR alone, measured by immunoblot of Triton‑X‑100 soluble fraction [5].

Conversely, AICAR treatment combined with lysosomotropic neutralizer (NH4Cl) will reduce p62‑positive puncta and increase lysosomal cathepsin activity, indicating restored flux.

Behavioral read‑out: mice receiving AICAR plus chloroquine will show accelerated decline in rotarod performance relative to AICAR‑only treated controls, linking oligomer release to functional deficit.

Falsification